Display options
Cite
Bonney EY, Lamptey H, Aboagye JO, et al. Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research. J Virus Erad. 2021;7(1):100027doi: 10.1016/j.jve.2020.100027.
Bonney, E. Y., Lamptey, H., Aboagye, J. O., Zaab-Yen Abana, C., Boateng, A. T., Quansah, D. N. K., Obo-Akwa, A., Ganu, V. J., Puplampu, P., Kyei, G. B. (2021). Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research. Journal of virus eradication, 7(1), 100027. https://doi.org/10.1016/j.jve.2020.100027
Bonney, Evelyn Y, et al. "Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research." Journal of virus eradication vol. 7,1 (2021): 100027. doi: https://doi.org/10.1016/j.jve.2020.100027
Bonney EY, Lamptey H, Aboagye JO, Zaab-Yen Abana C, Boateng AT, Quansah DNK, Obo-Akwa A, Ganu VJ, Puplampu P, Kyei GB. Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research. J Virus Erad. 2021 Jan 01;7(1):100027. doi: 10.1016/j.jve.2020.100027. eCollection 2021 Mar. PMID: 33437495; PMCID: PMC7788235.
Copy Download .nbib Format: NLM
Share it on

J Virus Erad. 2021 Jan 01;7(1):100027. doi: 10.1016/j.jve.2020.100027. eCollection 2021 Mar.

Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research.

Journal of virus eradication

Evelyn Y Bonney, Helena Lamptey, James O Aboagye, Christopher Zaab-Yen Abana, Anthony T Boateng, Darius N K Quansah, Adjoa Obo-Akwa, Vincent J Ganu, Peter Puplampu, George B Kyei,

Affiliations

  1. Department of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana.
  2. University of Ghana Medical School, College of Health Sciences, University of Ghana, Ghana.
  3. Department of Medicine, Washington University School of Medicine in St Louis, MO, USA.

PMID: 33437495 PMCID: PMC7788235 DOI: 10.1016/j.jve.2020.100027

Abstract

OBJECTIVES: Though antiretroviral therapy (ART) has reduced HIV infection into a manageable chronic disease, it does not provide for a cure. HIV cure trials may carry risks for patients who are generally doing well on ART, making it imperative that their input is sought as various types of cure methods and trials are designed. Few studies have sought the views of African patients on HIV cure studies. The objective of this study was to determine the views and preferences of people living with HIV (PLWH) in Ghana on cure research.

METHODS: We used a questionnaire to interview 251 PLWH in Ghana about their willingness to engage in HIV cure research. We investigated their motivations, the types of cure they would prefer and which risks were acceptable to them.

RESULTS: Most participants were enthusiastic about participating in cure research and driven by both altruistic and personal motives. Patients preferred a cure where they would continue follow-up with their doctor (88%) compared to being assured that they have been completely cured and did not need further follow-up (11%). The vast majority of the respondents were risk averse. Most patients (67%) would decline to interrupt ART as part of a protocol for HIV cure research. In bivariate analysis, participants above the age of 40 years were more likely to agree to treatment interruption during cure studies (OR 2.77; 95% CI 1.21-.6.34.

CONCLUSIONS: Our results show that preferred cure modalities and risk tolerance for patients in Africa may be different from those of other parts of the world. Extensive social science and behavioural studies are needed on the continent to help inform future cure trials.

© 2020 The Author(s).

Keywords: Antiretroviral therapy; Cure perception; HIV cure Research; Latency

Conflict of interest statement

The authors declare no conflicts of interest.

References

  1. J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S24-S26 - PubMed
  2. Lancet HIV. 2014 Oct;1(1):e13-21 - PubMed
  3. AIDS Behav. 2018 Jun;22(6):1792-1801 - PubMed
  4. Nat Rev Microbiol. 2016 Jan;14(1):55-60 - PubMed
  5. Viruses. 2020 Jan 10;12(1): - PubMed
  6. HIV Med. 2017 Feb;18(2):73-79 - PubMed
  7. J Int AIDS Soc. 2020 Feb;23(2):e25453 - PubMed
  8. J Virus Erad. 2019 Sep 18;5(3):152-162 - PubMed
  9. Cell. 2019 Oct 31;179(4):880-894.e10 - PubMed
  10. Top Antivir Med. 2020 Jan;27(4):91-95 - PubMed
  11. J Virus Erad. 2019 Apr 1;5(2):109-115 - PubMed
  12. Clin Infect Dis. 2015 Mar 15;60(6):937-40 - PubMed
  13. J Virus Erad. 2019 Apr 1;5(2):122-124 - PubMed
  14. mBio. 2019 Feb 5;10(1): - PubMed
  15. Cell Host Microbe. 2012 Jul 19;12(1):97-108 - PubMed
  16. EBioMedicine. 2017 Sep;23:52-58 - PubMed
  17. Biomed Res Int. 2017;2017:6096134 - PubMed
  18. Trends Immunol. 2019 May;40(5):375-377 - PubMed
  19. AIDS Care. 2016;28(4):524-7 - PubMed
  20. Nat Med. 2016 Aug;22(8):839-50 - PubMed
  21. Ethics Hum Res. 2019 Nov;41(6):23-34 - PubMed
  22. AIDS. 2016 Mar 13;30(5):N3 - PubMed
  23. Nat Commun. 2019 Jul 2;10(1):2753 - PubMed
  24. Curr Opin Infect Dis. 2014 Feb;27(1):29-35 - PubMed
  25. AIDS Rev. 2017 Oct-Dec;19(3):167-172 - PubMed
  26. Nat Rev Immunol. 2019 Jan;19(1):45-54 - PubMed
  27. BMC Infect Dis. 2016 Mar 03;16:109 - PubMed
  28. Curr Opin Virol. 2019 Oct;38:70-80 - PubMed
  29. Nature. 2012 Jul 25;487(7408):482-5 - PubMed
  30. Trends Immunol. 2017 Mar;38(3):217-228 - PubMed
  31. AIDS. 2014 May 15;28(8):1193-202 - PubMed

Publication Types